Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. [electronic resource]
Producer: 20030306Description: 3270-5 p. digitalISSN:- 1078-0432
- Animals
- Anticarcinogenic Agents -- therapeutic use
- Cells, Cultured
- Drug Synergism
- Drug Therapy, Combination
- Female
- Humans
- Mammary Neoplasms, Experimental -- metabolism
- Methylnitrosourea
- Neoplasm Invasiveness
- Nicotinic Acids -- therapeutic use
- Nitric Oxide Synthase -- metabolism
- Nitric Oxide Synthase Type II
- Piperidines -- therapeutic use
- Rats
- Selective Estrogen Receptor Modulators -- therapeutic use
- Stromal Cells -- metabolism
- Tetrahydronaphthalenes -- therapeutic use
- Thiophenes -- therapeutic use
- Transforming Growth Factor beta -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.